首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1689829篇
  免费   126503篇
  国内免费   3773篇
耳鼻咽喉   21743篇
儿科学   55608篇
妇产科学   46151篇
基础医学   240985篇
口腔科学   48727篇
临床医学   150805篇
内科学   332348篇
皮肤病学   38684篇
神经病学   131205篇
特种医学   63891篇
外国民族医学   242篇
外科学   257158篇
综合类   38883篇
现状与发展   4篇
一般理论   531篇
预防医学   123761篇
眼科学   40125篇
药学   123579篇
  7篇
中国医学   4476篇
肿瘤学   101192篇
  2021年   12782篇
  2019年   13541篇
  2018年   19966篇
  2017年   15232篇
  2016年   16632篇
  2015年   18989篇
  2014年   26242篇
  2013年   37981篇
  2012年   52801篇
  2011年   55497篇
  2010年   32817篇
  2009年   30736篇
  2008年   51583篇
  2007年   54866篇
  2006年   55362篇
  2005年   52611篇
  2004年   50841篇
  2003年   48254篇
  2002年   46462篇
  2001年   91845篇
  2000年   93675篇
  1999年   77034篇
  1998年   19749篇
  1997年   17291篇
  1996年   17411篇
  1995年   16763篇
  1994年   15283篇
  1993年   14014篇
  1992年   57346篇
  1991年   55292篇
  1990年   52990篇
  1989年   50765篇
  1988年   46147篇
  1987年   44964篇
  1986年   42220篇
  1985年   40009篇
  1984年   29323篇
  1983年   24858篇
  1982年   13855篇
  1979年   25491篇
  1978年   17541篇
  1977年   14859篇
  1976年   13834篇
  1975年   14525篇
  1974年   17609篇
  1973年   16921篇
  1972年   15673篇
  1971年   14436篇
  1970年   13417篇
  1969年   12510篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).

Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.

Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).

Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).

Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.

Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED.  相似文献   
92.
93.
94.
95.
A 17‐year‐old boy presented with recurring severe dermatitis of the face of 5‐months duration that resembled impetigo. He had been treated with several courses of antibiotics without improvement. Biopsy showed changes consistent with allergic contact dermatitis and patch testing later revealed sensitization to benzoyl peroxide, which the patient had been using for the treatment of acne vulgaris.  相似文献   
96.
97.
98.
Investigative studies of white matter (WM) brain structures using diffusion MRI (dMRI) tractography frequently require manual WM bundle segmentation, often called “virtual dissection.” Human errors and personal decisions make these manual segmentations hard to reproduce, which have not yet been quantified by the dMRI community. It is our opinion that if the field of dMRI tractography wants to be taken seriously as a widespread clinical tool, it is imperative to harmonize WM bundle segmentations and develop protocols aimed to be used in clinical settings. The EADC‐ADNI Harmonized Hippocampal Protocol achieved such standardization through a series of steps that must be reproduced for every WM bundle. This article is an observation of the problematic. A specific bundle segmentation protocol was used in order to provide a real‐life example, but the contribution of this article is to discuss the need for reproducibility and standardized protocol, as for any measurement tool. This study required the participation of 11 experts and 13 nonexperts in neuroanatomy and “virtual dissection” across various laboratories and hospitals. Intra‐rater agreement (Dice score) was approximately 0.77, while inter‐rater was approximately 0.65. The protocol provided to participants was not necessarily optimal, but its design mimics, in essence, what will be required in future protocols. Reporting tractometry results such as average fractional anisotropy, volume or streamline count of a particular bundle without a sufficient reproducibility score could make the analysis and interpretations more difficult. Coordinated efforts by the diffusion MRI tractography community are needed to quantify and account for reproducibility of WM bundle extraction protocols in this era of open and collaborative science.  相似文献   
99.
100.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号